For research use only. Not for therapeutic Use.
Ramelteon is the first in a new class of sleep agents that selectively binds to the MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), instead of binding to GABAA receptors, such as with drugs like zolpidem. Ramelteon is approved by the U.S. Food and Drug Administration (FDA) for long-term use. Ramelteon does not show any appreciable binding to GABAA receptors, which are associated with anxiolytic, myorelaxant, and amnesic effects. Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor.
| Catalog Number | A001192 |
| CAS Number | 196597-26-9 |
| Synonyms | TAK-375 |
| Molecular Formula | C16H21NO2 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | >13mg/mL in DMSO |
| Storage | 3 years -20C powder |
| InChIKey | YLXDSYKOBKBWJQ-LBPRGKRZSA-N |
| Reference | </br>1:Ramelteon Improves Post-traumatic Stress Disorder-Like Behaviors Exhibited by Fatty Acid-Binding Protein 3 Null Mice. Yabuki Y, Takahata I, Matsuo K, Owada Y, Fukunaga K.Mol Neurobiol. 2017 May 17. doi: 10.1007/s12035-017-0587-2. [Epub ahead of print] PMID: 28516430 </br>2:Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells. Osanai K, Kobayashi Y, Otsu M, Izawa T, Sakai K, Iwashita M.Hum Cell. 2017 Apr 5. doi: 10.1007/s13577-017-0169-7. [Epub ahead of print] PMID: 28382516 </br>3:A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients. Edmonds C, Swanoski M.Consult Pharm. 2017 Mar 1;32(3):156-160. doi: 10.4140/TCP.n.2017.156. PMID: 28270270 </br>4:Effectiveness of ramelteon for residual sleep disturbances (hypersomnia) in a patient with premenstrual dysphoric disorder. Yamada K.Psychiatry Clin Neurosci. 2017 Feb;71(2):147. doi: 10.1111/pcn.12484. Epub 2016 Dec 22. No abstract available. PMID: 27868343 </br>5:The Effects of Ramelteon on Glucose Metabolism and Sleep Quality in Type 2 Diabetic Patients With Insomnia: A Pilot Prospective Randomized Controlled Trial. Tsunoda T, Yamada M, Akiyama T, Minami T, Yoshii T, Kondo Y, Satoh S, Terauchi Y.J Clin Med Res. 2016 Dec;8(12):878-887. Epub 2016 Oct 26. PMID: 27829954 Free PMC Article</br>6:The Relief Effects of Ramelteon on Refractory Chronic Migraine: A Case Report. Hou YC, Lai CH.Clin Psychopharmacol Neurosci. 2016 Nov 30;14(4):405-406. doi: 10.9758/cpn.2016.14.4.405. PMID: 27776398 Free PMC Article</br>7:YIA 03-06 RAMELTEON ATTENUATES CARDIAC INJURY, IMPROVES INSULIN SIGNALING IN WHITE ADIPOSE TISSUE, AND ATTENUATES WHITENING OF BROWN ADIPOSE TISSUE IN RATS WITH METABOLIC SYNDROME. Uchinaka A, Kawashima Y, Sano Y, Yoneda M, Ito S, Sano Y, Nagasawa K, Matsuura N, Yamada Y, Murohara T, Nagata K.J Hypertens. 2016 Sep;34 Suppl 1 – ISH 2016 Abstract Book:e205. PMID: 27754030 </br>8:Efficacy of Ramelteon for delirium after lung cancer surgery. Miyata R, Omasa M, Fujimoto R, Ishikawa H, Aoki M.Interact Cardiovasc Thorac Surg. 2017 Jan;24(1):8-12. doi: 10.1093/icvts/ivw297. Epub 2016 Sep 13. PMID: 27624354 </br>9:A Cluster Headache Responsive to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist. Imai N.Intern Med. 2016;55(17):2483-5. doi: 10.2169/internalmedicine.55.6621. Epub 2016 Sep 1. PMID: 27580554 Free Article</br>10:Effective Treatment of Night Terrors and Sleepwalking with Ramelteon. Sasayama D, Washizuka S, Honda H.J Child Adolesc Psychopharmacol. 2016 Dec;26(10):948. Epub 2016 Jun 20. No abstract available. PMID: 27322726 |
